|
US5714167A
(en)
|
1992-06-15 |
1998-02-03 |
Emisphere Technologies, Inc. |
Active agent transport systems
|
|
US6099856A
(en)
|
1992-06-15 |
2000-08-08 |
Emisphere Technologies, Inc. |
Active agent transport systems
|
|
US6221367B1
(en)
|
1992-06-15 |
2001-04-24 |
Emisphere Technologies, Inc. |
Active agent transport systems
|
|
US5578323A
(en)
|
1992-06-15 |
1996-11-26 |
Emisphere Technologies, Inc. |
Proteinoid carriers and methods for preparation and use thereof
|
|
US5693338A
(en)
|
1994-09-29 |
1997-12-02 |
Emisphere Technologies, Inc. |
Diketopiperazine-based delivery systems
|
|
US6916489B2
(en)
*
|
1992-06-15 |
2005-07-12 |
Emisphere Technologies, Inc. |
Active agent transport systems
|
|
US6461643B2
(en)
|
1993-04-22 |
2002-10-08 |
Emisphere Technologies, Inc. |
Oral drug delivery compositions and methods
|
|
US20010003001A1
(en)
*
|
1993-04-22 |
2001-06-07 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
BR9604880A
(en)
|
1995-03-31 |
1998-05-19 |
Emisphere Tech Inc |
Compound composition dosage unit form methods for administering a biologically active agent for preparing a composition for administering an active agent and for preparing a compound and pharmacological composition
|
|
US5989539A
(en)
|
1995-03-31 |
1999-11-23 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
US5866536A
(en)
|
1995-03-31 |
1999-02-02 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
US6090958A
(en)
|
1995-03-31 |
2000-07-18 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
US6001347A
(en)
*
|
1995-03-31 |
1999-12-14 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
US5750147A
(en)
|
1995-06-07 |
1998-05-12 |
Emisphere Technologies, Inc. |
Method of solubilizing and encapsulating itraconazole
|
|
AU7072596A
(en)
|
1995-09-11 |
1997-04-01 |
Emisphere Technologies, Inc. |
Method for preparing omega-aminoalkanoic acid derivatives from cycloalkanones
|
|
AU2595697A
(en)
|
1996-03-29 |
1997-10-22 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
AU3828597A
(en)
|
1996-06-14 |
1998-01-07 |
Emisphere Technologies, Inc. |
Microencapsulated fragrances and method for preparation
|
|
CA2243643A1
(en)
|
1996-11-18 |
1998-05-28 |
Susan Haas |
Methods and compositions for inducing oral tolerance in mammals
|
|
US5990166A
(en)
|
1997-02-07 |
1999-11-23 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
PT993831E
(en)
*
|
1997-02-07 |
2008-02-12 |
Emisphere Tech Inc |
Compounds and compositions for delivering active agents
|
|
EP0993831B1
(en)
*
|
1997-02-07 |
2008-01-09 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
US5804688A
(en)
|
1997-02-07 |
1998-09-08 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
US6313088B1
(en)
|
1997-02-07 |
2001-11-06 |
Emisphere Technologies, Inc. |
8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
|
|
US6051561A
(en)
*
|
1997-02-07 |
2000-04-18 |
Emisphere Technologies Inc. |
Compounds and compositions for delivering active agents
|
|
US5879681A
(en)
|
1997-02-07 |
1999-03-09 |
Emisphere Technolgies Inc. |
Compounds and compositions for delivering active agents
|
|
US6358504B1
(en)
|
1997-02-07 |
2002-03-19 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
US5776888A
(en)
*
|
1997-02-07 |
1998-07-07 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
US5773647A
(en)
*
|
1997-02-07 |
1998-06-30 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
US6060513A
(en)
|
1997-02-07 |
2000-05-09 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
US5863944A
(en)
*
|
1997-04-30 |
1999-01-26 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
US5962710A
(en)
|
1997-05-09 |
1999-10-05 |
Emisphere Technologies, Inc. |
Method of preparing salicyloylamino acids
|
|
HUP0100397A3
(en)
*
|
1997-12-17 |
2002-10-28 |
Merck & Co Inc |
Tetrahydro- or octahydrobenzonaphtyridin and quinolin derivatives, pharmaceutical compositions thereof and process for their preparation
|
|
US6165458A
(en)
*
|
1997-12-26 |
2000-12-26 |
Pharmaderm Laboratories Ltd. |
Composition and method for dermal and transdermal administration of a cytokine
|
|
US6440929B1
(en)
|
1998-07-27 |
2002-08-27 |
Emisphere Technologies, Inc. |
Pulmonary delivery of active agents
|
|
JP4675481B2
(en)
|
1998-07-27 |
2011-04-20 |
エミスフェアー・テクノロジーズ・インク |
Pulmonary delivery of active agents
|
|
WO2000007979A2
(en)
*
|
1998-08-07 |
2000-02-17 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
US6991798B1
(en)
*
|
1998-08-07 |
2006-01-31 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
IL143962A0
(en)
*
|
1999-01-08 |
2002-04-21 |
Emisphere Tech Inc |
Polymeric delivery agents and delivery agent compounds
|
|
RU2233835C2
(en)
*
|
1999-02-05 |
2004-08-10 |
Эмисфере Текнолоджиз, Инк. |
Compounds and compositions for active agents delivery
|
|
EP1149066B1
(en)
|
1999-02-05 |
2005-11-09 |
Emisphere Technologies, Inc. |
Method of preparing alkylated salicylamides
|
|
US7084279B1
(en)
|
1999-02-11 |
2006-08-01 |
Emisphere Technologies Inc. |
Oxadiazole compounds and compositions for delivering active agents
|
|
US8119159B2
(en)
*
|
1999-02-22 |
2012-02-21 |
Merrion Research Iii Limited |
Solid oral dosage form containing an enhancer
|
|
US7658938B2
(en)
|
1999-02-22 |
2010-02-09 |
Merrion Reasearch III Limited |
Solid oral dosage form containing an enhancer
|
|
US20070148228A1
(en)
*
|
1999-02-22 |
2007-06-28 |
Merrion Research I Limited |
Solid oral dosage form containing an enhancer
|
|
WO2000048589A1
(en)
*
|
1999-02-22 |
2000-08-24 |
Emisphere Holdings, Inc. |
Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
|
|
EP1163209A4
(en)
*
|
1999-02-26 |
2004-12-29 |
Emisphere Tech Inc |
CONNECTIONS AND COMPOSITIONS FOR PROVIDING ACTIVE ACTIVE SUBSTANCES
|
|
DE60017888T2
(en)
*
|
1999-04-05 |
2006-01-19 |
Emisphere Technologies, Inc. |
DINATRIUM SALTS, MONOHYDRATE AND ETHANOL SOLVATE
|
|
US7129274B1
(en)
|
1999-11-05 |
2006-10-31 |
Emisphere Technologies Inc. |
Phenoxy carboxylic acid compounds and compositions for delivering active agents
|
|
US7279597B1
(en)
|
1999-11-05 |
2007-10-09 |
Emisphere Technologies, Inc. |
Phenyl amine carboxylic acid compounds and compositions for delivering active agents
|
|
WO2001032130A2
(en)
*
|
1999-11-05 |
2001-05-10 |
Emisphere Technologies, Inc. |
Phenyl amine carboxylic acid compounds and compositions for delivering active agents
|
|
DE20022960U1
(en)
*
|
1999-11-12 |
2002-07-25 |
Emisphere Technologies, Inc., Tarrytown, N.Y. |
Liquid heparin formulation
|
|
US6541661B1
(en)
|
1999-11-23 |
2003-04-01 |
Methylgene, Inc. |
Inhibitors of histone deacetylase
|
|
JP4850379B2
(en)
*
|
1999-12-16 |
2012-01-11 |
エミスフェアー・テクノロジーズ・インク |
Compounds and compositions for transporting active agents
|
|
JP4879433B2
(en)
|
2000-01-13 |
2012-02-22 |
エミスフェアー・テクノロジーズ・インク |
Compounds and compositions for delivering active agents
|
|
EP1299348B1
(en)
*
|
2000-06-29 |
2008-04-09 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
WO2003057650A2
(en)
|
2002-01-09 |
2003-07-17 |
Emisphere Technologies, Inc. |
Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate
|
|
US7495030B2
(en)
|
2000-09-06 |
2009-02-24 |
Emisphere Technologies, Inc. |
(5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
|
|
WO2002070438A2
(en)
*
|
2001-03-01 |
2002-09-12 |
Emisphere Technologies, Inc. |
Compositions for delivering bisphosphonates
|
|
US20030225300A1
(en)
*
|
2001-04-19 |
2003-12-04 |
Emisphere Technologies Inc. |
Compounds and compositions for delivering active agents
|
|
WO2002092616A1
(en)
*
|
2001-05-11 |
2002-11-21 |
Orasense, Ltd. |
Antisense permeation enhancers
|
|
CA2446622C
(en)
*
|
2001-05-11 |
2012-08-14 |
Elan Corporation, Plc |
Isostearic acid salts as permeation enhancers
|
|
HU229613B1
(en)
|
2001-06-01 |
2014-03-28 |
Novartis Ag |
Oral administration of parathyroid hormone and calcitonin
|
|
US20040259952A1
(en)
*
|
2001-11-29 |
2004-12-23 |
Richat Abbas |
Formulations for oral administration of cromolyn sodium
|
|
EP1455764B1
(en)
*
|
2001-12-21 |
2008-08-27 |
3M Innovative Properties Company |
Medicinal aerosol compositions with an amide and/or ester containing excipient compound
|
|
JP4417113B2
(en)
*
|
2002-02-20 |
2010-02-17 |
エミスフェアー・テクノロジーズ・インク |
Administration method of GLP-1 molecule
|
|
US20040072796A1
(en)
*
|
2002-04-18 |
2004-04-15 |
Embury Stephen H. |
Method and composition for preventing pain in sickle cell patients
|
|
CA2525168A1
(en)
*
|
2003-05-14 |
2004-12-02 |
Emisphere Technologies, Inc. |
Compositions for delivering peptide yy and pyy agonists
|
|
MXPA05013340A
(en)
*
|
2003-06-09 |
2006-03-09 |
Nastech Pharm Co |
Compositions and methods for enhanced mucosal delivery of growth hormone.
|
|
BRPI0412458A
(en)
*
|
2003-07-11 |
2006-10-17 |
Novartis Ag |
orally dosed pharmaceutical compositions comprising a release agent in micronized form
|
|
ES2222822B1
(en)
*
|
2003-07-28 |
2005-12-16 |
Laboratorios Farmaceuticos Rovi, S.A. |
DIAMIDES OF AMINO ACIDS IN NON-ALFA POSITION USEFUL AS ASSISTANTS FOR THE ADMINISTRATION OF ACTIVE BIOLOGICAL AGENTS.
|
|
ES2278346T3
(en)
|
2003-08-20 |
2007-08-01 |
Eli Lilly And Company |
COMPOUNDS, PROCEDURES AND FORMULATIONS FOR ORAL SUPPLY OF A PEPTIDE COMPOUND (LPG) -1 OF THE TYPE OF GLUCAGON OR AN AGONISTIC PEPTIDE (LPG) -4 OF THE RECEIVER 4 OF MELACORTINE (MC4).
|
|
WO2005019212A1
(en)
*
|
2003-08-20 |
2005-03-03 |
Eli Lilly And Company |
Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
|
|
US20060286129A1
(en)
*
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
|
EP1718145A4
(en)
|
2004-02-02 |
2012-03-07 |
Biosight Ltd |
Conjugates for cancer therapy and diagnosis
|
|
EP1750729A2
(en)
*
|
2004-05-06 |
2007-02-14 |
Emisphere Technologies, Inc. |
Solid dosage form of wetted heparin
|
|
EA013518B1
(en)
|
2004-05-06 |
2010-06-30 |
Эмисфире Текнолоджис, Инк. |
Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
|
|
CA2565188C
(en)
|
2004-05-14 |
2014-03-04 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
CA2566161C
(en)
*
|
2004-05-14 |
2013-10-01 |
Emisphere Technologies, Inc. |
Aryl ketone compounds and compositions for delivering active agents
|
|
US20050261241A1
(en)
*
|
2004-05-19 |
2005-11-24 |
Celsus Biopharmaceuticals, Inc. |
Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
|
|
NZ588373A
(en)
*
|
2004-05-19 |
2012-01-12 |
Emisphere Tech Inc |
Topical cromolyn formulations
|
|
EP1750718B1
(en)
|
2004-05-19 |
2014-08-13 |
Emisphere Technologies, Inc. |
Acyclovir formulations
|
|
CA2573512C
(en)
*
|
2004-07-12 |
2014-09-23 |
Emisphere Technologies, Inc. |
Compositions for delivering peptide yy and pyy agonists
|
|
AU2005271526B2
(en)
|
2004-08-03 |
2011-12-08 |
Emisphere Technologies, Inc. |
Antidiabetic oral insulin-biguanide combination
|
|
EP1781257B1
(en)
*
|
2004-08-13 |
2018-12-19 |
Emisphere Technologies, Inc. |
Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
|
|
CA2591515C
(en)
*
|
2004-12-29 |
2010-06-22 |
Emisphere Technologies, Inc. |
Pharmaceutical formulations of gallium salts
|
|
US8110547B2
(en)
|
2005-01-12 |
2012-02-07 |
Emisphere Technologies, Inc. |
Compositions for buccal delivery of parathyroid hormone
|
|
US8975227B2
(en)
*
|
2005-07-15 |
2015-03-10 |
Emisphere Technologies, Inc. |
Intraoral dosage forms of glucagon
|
|
US20070049557A1
(en)
*
|
2005-08-24 |
2007-03-01 |
Hashim Ahmed |
Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
|
|
CN101296694A
(en)
*
|
2005-11-04 |
2008-10-29 |
真塔公司 |
Pharmaceutical gallium compositions and methods
|
|
BRPI0710503A2
(en)
*
|
2006-04-07 |
2011-08-16 |
Merrion Res Iii Ltd |
use of a pharmaceutical composition, pharmaceutical composition, and oral dosage form
|
|
US8927015B2
(en)
*
|
2006-04-12 |
2015-01-06 |
Emisphere Technologies, Inc. |
Formulations for delivering insulin
|
|
US8771712B2
(en)
*
|
2006-05-09 |
2014-07-08 |
Emisphere Technologies, Inc. |
Topical administration of acyclovir
|
|
EP2040731A4
(en)
*
|
2006-06-09 |
2010-05-19 |
Merrion Res Iii Ltd |
Solid oral dosage form containing an enhancer
|
|
CA2656019C
(en)
*
|
2006-06-28 |
2016-09-13 |
Emisphere Technologies, Inc. |
Gallium nitrate formulations
|
|
ES2296529B1
(en)
*
|
2006-08-07 |
2009-04-01 |
Laboratorios Farmaceuticos Rovi, S.A. |
PHARMACEUTICAL COMPOSITION WITH ABSORPTION PROMOTERS.
|
|
US8895777B2
(en)
*
|
2006-08-31 |
2014-11-25 |
Emisphere Technologies Inc |
Compounds and compositions for delivering active agents
|
|
KR101081149B1
(en)
|
2006-09-07 |
2011-11-07 |
에미스페어 테크놀로지스, 인코포레이티드 |
A process for the manufacture of snac (salcaprozate sodium)
|
|
GB0621973D0
(en)
*
|
2006-11-03 |
2006-12-13 |
Philogen Spa |
Binding molecules and uses thereof
|
|
EP2118123B1
(en)
|
2007-01-31 |
2015-10-14 |
Dana-Farber Cancer Institute, Inc. |
Stabilized p53 peptides and uses thereof
|
|
PL2134351T3
(en)
|
2007-03-13 |
2017-10-31 |
Jds Therapeutics Llc |
Methods and compositions for the sustained release of chromium
|
|
EP3159352B1
(en)
|
2007-03-28 |
2023-08-02 |
President and Fellows of Harvard College |
Stitched polypeptides
|
|
WO2009002867A2
(en)
|
2007-06-26 |
2008-12-31 |
Nutrition 21, Inc. |
Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
|
|
PL2215047T3
(en)
|
2007-11-02 |
2014-05-30 |
Emisphere Tech Inc |
Method of treating vitamin b12 deficiency
|
|
JP5484316B2
(en)
*
|
2008-02-28 |
2014-05-07 |
財団法人乙卯研究所 |
Aromatic amide derivatives
|
|
DE102008018675A1
(en)
|
2008-04-14 |
2009-10-15 |
Bayer Schering Pharma Aktiengesellschaft |
Oxo-heterocyclic substituted carboxylic acid derivatives and their use
|
|
US20090280169A1
(en)
*
|
2008-05-07 |
2009-11-12 |
Merrion Research Iii Limited |
Compositions of peptides and processes of preparation thereof
|
|
WO2010072228A1
(en)
*
|
2008-12-22 |
2010-07-01 |
Xigen S.A. |
Novel transporter constructs and transporter cargo conjugate molecules
|
|
TWI480286B
(en)
*
|
2009-02-25 |
2015-04-11 |
Merrion Res Iii Ltd |
Composition and drug delivery of bisphosphonates
|
|
DE102009012314A1
(en)
|
2009-03-09 |
2010-09-16 |
Bayer Schering Pharma Aktiengesellschaft |
Oxo-heterocyclic substituted alkylcarboxylic acids and their use
|
|
US20110039930A1
(en)
|
2009-08-03 |
2011-02-17 |
Emisphere Technologies, Inc. |
Fast-acting naproxen composition with reduced gastrointestinal effects
|
|
DE102009046115A1
(en)
|
2009-10-28 |
2011-09-08 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted 3-phenylpropanoic acids and their use
|
|
CA2775631A1
(en)
*
|
2009-10-28 |
2011-05-05 |
Xellia Pharmaceuticals Aps |
2-amino-3-methyl-hex-5-enoic acid and its use in the production of peptides such as bacitracins
|
|
US20110182985A1
(en)
*
|
2010-01-28 |
2011-07-28 |
Coughlan David C |
Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
|
|
US20110207693A1
(en)
*
|
2010-02-24 |
2011-08-25 |
Emisphere Technologies, Inc. |
Oral B12 Therapy
|
|
WO2011120033A1
(en)
*
|
2010-03-26 |
2011-09-29 |
Merrion Research Iii Limited |
Pharmaceutical compositions of selective factor xa inhibitors for oral administration
|
|
KR102104762B1
(en)
|
2010-08-13 |
2020-04-24 |
에일러론 테라퓨틱스 인코포레이티드 |
Peptidomimetic macrocycles
|
|
ES2544532T3
(en)
|
2010-12-07 |
2015-09-01 |
Bayer Intellectual Property Gmbh |
Substituted 1-benzylcycloalkylcarboxylic acids and their use
|
|
RU2600440C3
(en)
|
2010-12-16 |
2021-12-10 |
Ново Нордиск А/С |
SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N- (8- (2-HYDROXYBENZOYL) AMINO) CAPRYLIC ACID SALT
|
|
AU2012204213A1
(en)
|
2011-01-07 |
2013-06-13 |
Merrion Research Iii Limited |
Pharmaceutical compositions of iron for oral administration
|
|
US8618125B2
(en)
|
2011-01-14 |
2013-12-31 |
Heptiva LLC |
Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers and liver health maintenance
|
|
AU2012223282B2
(en)
|
2011-03-01 |
2017-02-02 |
Nutrition 21, Llc |
Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
|
|
WO2012130193A1
(en)
|
2011-03-31 |
2012-10-04 |
Zentiva, K.S. |
Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
|
|
DE102011007272A1
(en)
|
2011-04-13 |
2012-10-18 |
Bayer Pharma Aktiengesellschaft |
Branched 3-phenylpropionic acid derivatives and their use
|
|
KR102038300B1
(en)
*
|
2011-06-08 |
2019-10-31 |
닛토덴코 가부시키가이샤 |
COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY
|
|
US9011903B2
(en)
|
2011-06-08 |
2015-04-21 |
Nitto Denko Corporation |
Cationic lipids for therapeutic agent delivery formulations
|
|
TW201806968A
(en)
|
2011-10-18 |
2018-03-01 |
艾利倫治療公司 |
Peptidomimetic macrocycles
|
|
NZ627528A
(en)
|
2012-02-15 |
2016-05-27 |
Aileron Therapeutics Inc |
Peptidomimetic macrocycles
|
|
CA2864120A1
(en)
|
2012-02-15 |
2013-08-22 |
Aileron Therapeutics, Inc. |
Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
|
|
SI3677252T1
(en)
|
2012-03-19 |
2024-02-29 |
Cidara Therapeutics, Inc. |
Dosing regimens for echinocandin class compounds
|
|
US10933120B2
(en)
|
2012-03-22 |
2021-03-02 |
Novo Nordisk A/S |
Compositions of GLP-1 peptides and preparation thereof
|
|
HUE064694T2
(en)
|
2012-03-22 |
2024-04-28 |
Novo Nordisk As |
Compositions comprising a delivery agent and preparation thereof
|
|
DE102012208530A1
(en)
|
2012-05-22 |
2013-11-28 |
Bayer Pharma AG |
Substituted piperidinoacetamides and their use
|
|
RS62288B9
(en)
*
|
2012-06-08 |
2021-12-31 |
Nitto Denko Corp |
Lipids for therapeutic agent delivery formulations
|
|
BR112015006176B1
(en)
|
2012-09-21 |
2023-04-18 |
Intensity Therapeutics, Inc |
USE OF A THERAPEUTIC AGENT AND AN INTRACELLULAR PERMEATION ENHANCEMENT AGENT
|
|
BR112015009470A2
(en)
|
2012-11-01 |
2019-12-17 |
Aileron Therapeutics Inc |
disubstituted amino acids and their methods of preparation and use
|
|
CN107573275A
(en)
*
|
2012-12-28 |
2018-01-12 |
日本脏器制药株式会社 |
Cinnamamide derivative
|
|
AU2014261336B2
(en)
|
2013-05-02 |
2019-02-28 |
Novo Nordisk A/S |
Oral dosing of GLP-1 compounds
|
|
KR20170058424A
(en)
|
2014-09-24 |
2017-05-26 |
에일러론 테라퓨틱스 인코포레이티드 |
Peptidomimetic macrocycles and uses thereof
|
|
JP7211704B2
(en)
|
2015-01-29 |
2023-01-24 |
ノヴォ ノルディスク アー/エス |
A tablet containing a GLP-1 agonist and an enteric coating
|
|
CN114949185A
(en)
|
2015-02-09 |
2022-08-30 |
安特拉贝欧有限公司 |
Osteoporosis Treatment
|
|
SG11201707750YA
(en)
|
2015-03-20 |
2017-10-30 |
Aileron Therapeutics Inc |
Peptidomimetic macrocycles and uses thereof
|
|
US12071450B2
(en)
|
2015-12-03 |
2024-08-27 |
Biosight Ltd. |
Salts of conjugates for cancer therapy
|
|
CA3007065C
(en)
|
2015-12-03 |
2023-02-14 |
Biosight Ltd. |
Salts of conjugates for cancer therapy
|
|
AU2016362830B2
(en)
|
2015-12-03 |
2022-07-14 |
Biosight Ltd. |
Cytarabine conjugates for cancer therapy
|
|
US12064445B2
(en)
|
2015-12-03 |
2024-08-20 |
Biosight Ltd. |
Cytarabine conjugates for cancer therapy
|
|
EP3413900A1
(en)
|
2016-02-11 |
2018-12-19 |
Nutrition 21, LLC |
Chromium containing compositions for improving health and fitness
|
|
US10588974B2
(en)
*
|
2016-04-22 |
2020-03-17 |
Receptor Holdings, Inc. |
Fast-acting plant-based medicinal compounds and nutritional supplements
|
|
NZ751668A
(en)
|
2016-08-17 |
2022-07-29 |
Entera Bio Ltd |
Formulations for oral administration of active agents
|
|
EA201892396A1
(en)
*
|
2016-12-02 |
2019-04-30 |
Ресептор Лайф Сайенсиз, Инк. |
QUICKLY PRODUCTIVE PLANT MEDICINES AND BIOLOGICALLY ACTIVE ADDITIVES
|
|
TWI797133B
(en)
|
2017-06-09 |
2023-04-01 |
丹麥商諾佛 儂迪克股份有限公司 |
Solid compositions for oral administration
|
|
JP2020527159A
(en)
|
2017-07-19 |
2020-09-03 |
ノヴォ ノルディスク アー/エス |
EGF (A) analogs, their manufacture, formulation and use
|
|
BR112020014624A2
(en)
|
2018-02-02 |
2020-12-08 |
Novo Nordisk A/S |
SOLID COMPOSITIONS UNDERSTANDING GLP-1 AGONIST, CAPRILIC AND LUBRICANT N- (8- (2-HYDROXYBENZOIL) AMINO ACID SALT)
|
|
TWI829687B
(en)
|
2018-05-07 |
2024-01-21 |
丹麥商諾佛 儂迪克股份有限公司 |
Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
|
|
US10905667B2
(en)
|
2018-07-24 |
2021-02-02 |
Bayer Pharma Aktiengesellschaft |
Orally administrable modified-release pharmaceutical dosage form
|
|
US12303487B2
(en)
|
2018-11-19 |
2025-05-20 |
Spoke Sciences, Inc. |
N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
|
|
EP4009958A1
(en)
|
2019-08-07 |
2022-06-15 |
Novo Nordisk A/S |
Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
|
|
WO2021043971A1
(en)
|
2019-09-06 |
2021-03-11 |
Novo Nordisk A/S |
Method and equipment for fractionation of granules for use in pharmaceutical compositions
|
|
RS65780B1
(en)
|
2019-11-06 |
2024-08-30 |
Novo Nordisk As |
Semaglutide in the treatment of alzheimer's dementia
|
|
JP2023500031A
(en)
|
2019-11-07 |
2023-01-04 |
ノヴォ ノルディスク アー/エス |
Solid composition comprising a PCSK9 inhibitor and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
|
|
CN114641276A
(en)
|
2019-11-07 |
2022-06-17 |
诺和诺德股份有限公司 |
Solid compositions comprising a GLP-1 agonist, an SGLT2 inhibitor, and a salt of N- (8- (2-hydroxybenzoyl) amino) caprylic acid
|
|
US11478533B2
(en)
|
2020-04-27 |
2022-10-25 |
Novo Nordisk A/S |
Semaglutide for use in medicine
|
|
JP7777085B2
(en)
|
2020-04-29 |
2025-11-27 |
ノヴォ ノルディスク アー/エス |
Solid Composition Comprising a GLP-1 Agonist and Histidine - Patent application
|
|
WO2021238088A1
(en)
|
2020-05-29 |
2021-12-02 |
杭州先为达生物科技有限公司 |
N-[8-(2-hydroxybenzoyl)amino]potassium octanoate crystal polymorph, and preparation method therefor and use thereof
|
|
CR20230308A
(en)
|
2020-12-11 |
2023-09-08 |
Civi Biopharma Inc |
ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETTING PCSK9
|
|
CN116887815A
(en)
|
2021-02-12 |
2023-10-13 |
美德阿利克斯株式会社 |
Compositions with improved absorption of poorly absorbable drugs
|
|
US11667614B2
(en)
|
2021-04-16 |
2023-06-06 |
Navinta III Inc. |
Process for the preparation of highly pure Salcaprozic Acid and pharmaceutically acceptable salts thereof
|
|
WO2022221629A1
(en)
|
2021-04-16 |
2022-10-20 |
Navinta Iii Inc |
Process for the preparation of highly pure salcaprozic acid and pharmaceutically acceptable salts thereof
|
|
IL307875A
(en)
|
2021-04-22 |
2023-12-01 |
Civi Biopharma Inc |
Oral delivery of oligonucleotides
|
|
CN117561072A
(en)
|
2021-06-25 |
2024-02-13 |
甘李药业股份有限公司 |
Pharmaceutical compositions containing GLP-1 compounds
|
|
MX2024000768A
(en)
|
2021-07-15 |
2024-02-12 |
Novo Nordisk As |
Tablet comprising a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid.
|
|
WO2023012263A1
(en)
|
2021-08-04 |
2023-02-09 |
Novo Nordisk A/S |
Solid oral peptide formulations
|
|
WO2024110614A1
(en)
|
2022-11-25 |
2024-05-30 |
Novo Nordisk A/S |
Oral administration of peptide therapeutics, such as glp-1
|
|
EP4642440A1
(en)
|
2022-12-30 |
2025-11-05 |
Algipharma As |
Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
|
|
WO2025141508A1
(en)
*
|
2023-12-27 |
2025-07-03 |
Olon S.P.A. |
Process for preparing salcaprozate sodium
|
|
WO2025169190A2
(en)
|
2024-02-06 |
2025-08-14 |
Opko Biologics Ltd. |
Modified oxyntomodulin and methods of use thereof
|